Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 8/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244183 | 1.00 | NR1H2 (0.50) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL1585055 | 1.00 | NR1H2 (0.50) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL12808018 | 1.00 | NR1H2 (0.50) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL12240671 | 0.91 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL1710964 | 0.91 | NR1H2 (0.56) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL19943157 | 0.87 | NR1H2 (0.49) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL26430598 | 0.85 | NR1H2 (0.44) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL21845527 | 0.85 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL21887306 | 0.85 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL21845181 | 0.85 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | NR1H2 160/4885SRC 2794/4885CHRM2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.